Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Erlotinib is an epidermal growth factor receptor inhibitor approved for patients with advanced non-small-cell lung cancer (NSCLC) whose epidermal growth factor receptor expression status is positive or unknown. Although it is efficacious, erlotinib can cause skin toxicity. This prospective, randomized phase III trial examined the effect of prophylactic treatment of erlotinib-induced skin rash.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Clin. Oncol.

Title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

ISSN (Electronic): 1527-7755

ISSN (Print): 0732-183X

Publication date (Electronic): Mar 10 2016

Volume: 34

Issue: 8

Affiliations

[1 ] Barbara Melosky, Vincent Ho, Cheryl Ho, Nevin Murray, Sophie Sun, and Janessa J. Laskin, British Columbia Cancer Agency (BCCA) Vancouver Centre, Vancouver; Helen Anderson, BCCA Vancouver Island Centre, Victoria; Wendy Lam, Burnaby Regional Hospital, Burnaby; Christopher W. Lee, BCCA Fraser Valley Cancer Centre, Surrey; Robert Winston, BCCA Abbotsford Centre, Abbotsford, British Columbia; Ronald L. Burkes, Mount Sinai Hospital; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario; Quincy Chu, Cross Cancer Institute, Edmonton; and Desiree Hao, Tom Baker Care Centre, Calgary, Alberta, Canada. bmelosky@bccancer.bc.ca.

[2 ] Barbara Melosky, Vincent Ho, Cheryl Ho, Nevin Murray, Sophie Sun, and Janessa J. Laskin, British Columbia Cancer Agency (BCCA) Vancouver Centre, Vancouver; Helen Anderson, BCCA Vancouver Island Centre, Victoria; Wendy Lam, Burnaby Regional Hospital, Burnaby; Christopher W. Lee, BCCA Fraser Valley Cancer Centre, Surrey; Robert Winston, BCCA Abbotsford Centre, Abbotsford, British Columbia; Ronald L. Burkes, Mount Sinai Hospital; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario; Quincy Chu, Cross Cancer Institute, Edmonton; and Desiree Hao, Tom Baker Care Centre, Calgary, Alberta, Canada.

Article

Publisher Item ID: JCO.2015.62.3918

DOI: 10.1200/JCO.2015.62.3918

PubMed ID: 26573073

SO-VID: d8580e29-c122-4eff-a2bc-125e3dfcae32

History

Data availability:

Comments

Comment on this article

scite_

Cited by 26

See all cited by